Flu Vaccine Linked to Lower Cardiovascular Risk

 

Flu Vaccine Linked to Lower Cardiovascular Risk

 

NBN Infusions delivers comprehensive services to patients of all ages, from pediatric to geriatric, providing a full range of care for Home Infusion Therapy. NBN Infusions on-site, licensed pharmacy can provide prescription medications, equipment, supplies and skilled nursing care needed for Home Infusion Therapy.

Home Infusion Therapy is a more convenient and cost-effective option than traditional inpatient therapy, with care administered in the comfortable surroundings of one’s own home. Home Infusion Therapy allows for a more active role in one’s own health care. It can also ease stress and anxiety that is sometimes associated with inpatient treatment, resulting in better patient outcomes.

 

Influenza vaccination is associated with a lower risk of cardiovascular events among those at high risk of cardiovascular disease, particularly among those with more active coronary disease, according to a review and meta-analysis published in the Oct. 23/30 issue of the Journal of the American Medical Association.

 

Jacob A. Udell, M.D., M.P.H., from the University of Toronto, and colleagues identified and performed a meta-analysis of five published and one unpublished randomized clinical trials involving 6,735 patients at high risk of cardiovascular disease and comparing influenza vaccine versus placebo or control. The mean follow-up time was 7.9 months.

 

The researchers found that influenza vaccination was associated with a significantly lower risk of composite cardiovascular events (2.9 versus 4.7 percent; relative risk 0.64). The lower risk was largely confined to patients with a recent history of acute coronary syndrome (within one year of randomization; relative risk, 0.45; P < 0.001) compared to those without a recent history of acute coronary syndrome (relative risk, 0.94; P = 0.81).

 

“In a meta-analysis of randomized clinical trials, the use of influenza vaccine was associated with a lower risk of major adverse cardiovascular events,” Udell and colleagues conclude. “The greatest treatment effect was seen among the highest-risk patients with more active coronary disease.”

 

Several authors disclosed financial relationships with pharmaceutical companies.

  

Original post: PhysiciansBriefings.com 

 

 

Enhanced by Zemanta